Frailty appears to modify the relationship between Alzheimer’s disease pathology and Alzheimer’s dementia, with increased levels making people more susceptible to clinical disease.
US researchers have used population-based data to predict an individual’s absolute risk of developing cognitive impairment according to imaging-based biomarkers of amyloid and neuronal injury.
Over a third of patients tested for dementia in the primary care setting may be misclassified due to specific biases in commonly used brief cognitive tests, study findings indicate.
Dementia is the proximate cause of death in 70% of older adults with Down’s syndrome, show findings from a large community-based study published in JAMA Neurology.
Elevated cerebrospinal fluid neurofilament light levels are associated with an increased risk of mild cognitive impairment, indicate findings from a population-based study.
Study findings show an increased risk of dementia in older people with atrial fibrillation and support the use of anticoagulants to reduce the likelihood.
The positron emission tomography tracer [18F]flortaucipir could be a useful test for distinguishing Alzheimer’s disease from other neurodegenerative disorders, say researchers.
Plasma neurofilament light protein concentrations and cerebrospinal fluid biomarkers are effective for diagnosing Alzheimer’s disease in patients with Down syndrome, say researchers.
Living close to major roads is associated with an increased risk for dementia, but not for Parkinson’s disease or multiple sclerosis, study findings reported in The Lancet show.
Albuminuria is modestly associated with the risk for dementia, researchers report in findings supporting the view that cognitive decline and renal dysfunction may be linked.
A first-in-human clinical trial of an active vaccine targeting pathologic tau protein in patients with Alzheimer’s disease has shown the vaccine elicits a well-tolerated, strong, and specific immune response.
The addition of 2 years of in-home occupational therapy to collaborative care does not provide functional benefits for patients with Alzheimer’s disease.
The prevalence of dementia in the USA has decreased between 2000 and 2012, and increasing educational attainment appears to be one of the contributing factors.
Phase III trial results suggest there is no benefit to adding tau-aggregation inhibitor therapy to standard treatment in patients with mild to moderate Alzheimer’s disease.
Preserved hippocampal volume could distinguish which patients with mild cognitive impairment are likely to develop dementia with Lewy bodies rather than Alzheimer’s disease, researchers report.